An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites by Rebecca Pharaon, Samuel Chung, Arya Amini, Ellie Maghami, Arnab Chowdhury, Nayana Vora, Sue Chang, Robert Kang, Thomas Gernon, Kelly Hansen, Christina Kelly, Denise Ackerman, Lalit Vora, Sagus Sampath, Erminia Massarelli

Get full text

Loss-of-function mutation in PRMT9 causes abnormal synapse development by dysregulation of RNA alternative splicing by Lei Shen, Xiaokuang Ma, Yuanyuan Wang, Zhihao Wang, Yi Zhang, Hoang Quoc Hai Pham, Xiaoqun Tao, Yuehua Cui, Jing Wei, Dimitri Lin, Tharindumala Abeywanada, Swanand Hardikar, Levon Halabelian, Noah Smith, Taiping Chen, Dalia Barsyte-Lovejoy, Shenfeng Qiu, Yi Xing, Yanzhong Yang

Get full text

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma by Surbhi Sidana, Hitomi Hosoya, Alexandria Jensen, Lawrence Liu, Anmol Goyal, Vanna Hovanky, Bita Sahaf, Sushma Bharadwaj, Theresa Latchford, Sally Arai, Sheryl Leahy, Matthew Mei, Lihua E. Budde, Lori S. Muffly, Matthew J. Frank, Saurabh Dahiya, Myo Htut, David Miklos, Murali Janakiram

Get full text

Prenatal correction of IGF2 to rescue the growth phenotypes in mouse models of Beckwith-Wiedemann and Silver-Russell syndromes by Ji Liao, Tie-Bo Zeng, Nicholas Pierce, Diana A. Tran, Purnima Singh, Jeffrey R. Mann, Piroska E. Szabó

Get full text

Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth by Mari B. Ishak Gabra, Ying Yang, Haiqing Li, Parijat Senapati, Eric A. Hanse, Xazmin H. Lowman, Thai Q. Tran, Lishi Zhang, Linda T. Doan, Xiangdong Xu, Dustin E. Schones, David A. Fruman, Mei Kong

Get full text

603 Phase II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): big ten cancer research consortium (BTCRC-LU... by Jyoti Malhotra, Alberto Chiappori, Salma K Jabbour, Chunxia Chen, Naomi Fujioka, Nasser H Hanna, Lawrence E Feldman, Malini Patel, Dirk Moore

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABE... by A. Maiolino, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

Get full text

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY by Thierry Facon, Philippe Moreau, Ivan Špicka, Kenshi Suzuki, Kwee Yong, Joseph Mikhael, Taro Fukao, Kamlesh Bisht, Nicole Armstrong, Sandrine Macé, Marie-Laure Risse, Thomas Martin

Get full text

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-lab... by M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

Get full text

P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG C... by M. Wang, M. Mei, P. M. Barr, J. Barrientos, S. de Vos, R. Furman, K. Patel, P. A. Thompson, M. Choi, A. Kallam, Y. Zhu, S. Chakraborty, P. Marinello, S. E. Spurgeon

Get full text

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients by Rodrigo Fonseca, Mariano Arribas, Julia E. Wiedmeier-Nutor, Yael N. Kusne, Miguel González Vélez, Heidi E. Kosiorek, Richard (Duke) J. Butterfield, Ilan R. Kirsch, Joseph R. Mikhael, A. Keith Stewart, Craig Reeder, Jeremy Larsen, P. Leif Bergsagel, Rafael Fonseca

Get full text

Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements by Michael L Levy, Allen L Ho, Samuel Hughes, Jayant Menon, Rahul Jandial

“…Michael L Levy1, Allen L Ho1,2, Samuel Hughes3, Jayant Menon1, Rahul Jandial41Division of Neurosurgery, University of California, San Diego, La Jolla, California, USA; 2Del E Webb Neurosciences, Aging and Stem Cell Research Center, The Burnham Institute for Medical Research, La Jolla, California, USA; 3Department of Neurological Surgery, Oregon Health and Science University, Portland, OR, USA; 4Division of Neurosurgery, Department of Surgery, City of Hope Cancer Center, Duarte, CA, USAAbstract: The biology of both normal and tumor development clearly possesses overlapping and parallel features. …”
Get full text

601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel... by Aditi Qamra, Hartmut Koeppen, Fabrice Barlesi, Federico Cappuzzo, Martin Reck, Mark A Socinski, Marcus Ballinger, Robert M Jotte, Barzin Nabet, Minu K Srivastava, Soren Muller, Tianshi Lu, Howard West, Habib Hamidi, Assaf Amitai, David S Shames

Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy by Song Yang, Yumeng Sun, Wei Liu, Yi Zhang, Guozhu Sun, Bai Xiang, Jiankai Yang

Get full text

Addressing the disparities: the approach to the African American patient with multiple myeloma by Manisha Bhutani, Brandon J. Blue, Craig Cole, Ashraf Z. Badros, Saad Z. Usmani, Ajay K. Nooka, Leon Bernal-Mizrachi, Joseph Mikhael

Get full text

Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience by Miguel A. Villalona-Calero, Jyoti Malhotra, Vincent Chung, Yan Xing, Stacy W. Gray, Heather Hampel, Stephen Gruber, Kevin McDonnell

“…Here, we describe ongoing efforts at the City of Hope Cancer Center to integrate our network community oncology clinical practices into our academic, centralized biomarker/genomic-driven, early-stage clinical trial program to build an understanding of the approaches that provide the benefits of early-stage clinical trial participation to community patients. …”
Get full text

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study by Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau

Get full text

Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial by Arta M. Monjazeb, Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina, Alexander Borowsky, Amin Mirhadi, Stephen L. Shiao, Laurel Beckett, Shuai Chen, David Eastham, Tianhong Li, Logan V. Vick, Heather M. McGee, Frances Lara, Leslie Garcia, Leigh Anne Morris, Robert J. Canter, Jonathan W. Riess, Kurt A. Schalper, William J. Murphy, Karen Kelly

Get full text

Factors contributing to disparities in mortality among patients with non–small‐cell lung cancer by Anish J. Mehta, Shannon Stock, Stacy W. Gray, David R. Nerenz, John Z. Ayanian, Nancy L. Keating

Get full text

Brain Tumor Tropism of Transplanted Human Neural Stem Cells Is Induced by Vascular Endothelial Growth Factor by Nils Ole Schmidt, Wojciech Przylecki, Wendy Yang, Mateo Ziu, Yang Teng, Seung U. Kim, Peter Mcl. Black, Karen S. Aboody, Rona S. Carroll

Get full text